News

High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.

Physicians at VCU's Massey Comprehensive Cancer Center explored their experiences using tumor-infiltrating lymphocytes to treat patients with advanced melanoma.

The FDA approves new denosumab biosimilars, expanding treatment options for osteoporosis and cancer-related bone issues, enhancing patient access to care.

The FDA reviews zidesamtinib for advanced ROS1+ NSCLC, promising new treatment options for patients resistant to current therapies.

A novel combination therapy shows promising results in extending progression-free survival for patients with advanced pancreatic cancer, highlighting potential biomarkers for immunotherapy.

New research reveals that high CD8-positive T-cell infiltration worsens outcomes for ovarian cancer patients treated with bevacizumab, challenging existing prognostic models.

Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options.

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

The FDA has approved daratumumab and hyaluronidase plus chemotherapy for treating patients with newly diagnosed light chain amyloidosis.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia, enhancing patient outcomes.

A novel sandwich therapy combining CD22/CD19 CAR T-cell therapy and autologous stem cell transplantation shows remarkable efficacy in treating Ph-negative B-ALL.

The FDA approves selumetinib for adults with neurofibromatosis type 1, offering new hope for treating inoperable plexiform neurofibromas.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

Giredestrant shows promise as a groundbreaking treatment for early-stage breast cancer, significantly improving disease-free survival rates.

Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ED visits and improving treatment adherence through effective symptom management.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens for non–clear cell renal cell carcinoma.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

Small cell lung cancer treatment evolves with groundbreaking therapies, improving survival rates and offering new hope for patients in 2024 and beyond.

The FDA approves epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a new second-line treatment option.

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

A phase 1b/2 trial shows triplet therapy for advanced renal cell carcinoma is feasible but lacks significant response improvement over standard treatment.

The FDA grants fast track designation to a new noninvasive diagnostic agent for clear cell renal cell carcinoma, promising improved patient outcomes.

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer care.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

At the 43rd Annual CFS meeting, John Allan, MD, highlighted ongoing efforts to advance the treatment paradigm for chronic lymphocytic leukemia.